Impact of Ceftolozane–Tazobactam vs. Best Alternative Therapy on Clinical Outcomes in Patients with Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Lower Respiratory Tract Infections

被引：0
|
作者：
Dana J. Holger
Nicholas S. Rebold
Sara Alosaimy
Taylor Morrisette
Abdalhamid Lagnf
Ana Christine Belza
Ashlan J. Kunz Coyne
Amer El Ghali
Michael P. Veve
Michael J. Rybak
机构：
[1] Wayne State University,Anti
[2] Wayne State University,Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences
[3] Henry Ford Hospital,Department of Pharmacy
[4] Detroit Receiving Hospital,Department of Pharmacy Services
[5] Detroit Medical Center,School of Medicine
[6] Wayne State University,Department of Clinical Pharmacy and Outcomes Sciences, College of Pharmacy
[7] Seres Therapeutics,Department of Pharmacy Services
[8] Medical University of South Carolina,undefined
[9] Medical University of South Carolina Shawn Jenkins Children’s Hospital,undefined
来源：
Infectious Diseases and Therapy | 2022年 / 11卷
关键词：
Ceftolozane–tazobactam; HABP/VABP; Multidrug resistance; Pneumonia;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1965 / 1980
页数：15
相关论文
共 50 条
  • [1] Impact of Ceftolozane-Tazobactam vs. Best Alternative Therapy on Clinical Outcomes in Patients with Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Lower Respiratory Tract Infections
    Holger, Dana J.
    Rebold, Nicholas S.
    Alosaimy, Sara
    Morrisette, Taylor
    Lagnf, Abdalhamid
    Belza, Ana Christine
    Coyne, Ashlan J. Kunz
    El Ghali, Amer
    Veve, Michael P.
    Rybak, Michael J.
    INFECTIOUS DISEASES AND THERAPY, 2022, 11 (05) : 1965 - 1980
  • [2] Ceftolozane/Tazobactam Therapy of Respiratory Infections due to Multidrug-Resistant Pseudomonas aeruginosa
    Gelfand, Michael S.
    Cleveland, Kerry O.
    CLINICAL INFECTIOUS DISEASES, 2015, 61 (05) : 853 - U207
  • [3] Use of ceftolozane/tazobactam as salvage therapy for infections due to extensively drug-resistant Pseudomonas aeruginosa
    Dinh, Aurelien
    Wyplosz, Benjamin
    Kerneis, Solen
    Lebeaux, David
    Bouchand, Frederique
    Duran, Clara
    Beraud, Guillaume
    Lazaro, Pauline
    Davido, Benjamin
    Henard, Sandrine
    Canoui, Etienne
    Ferry, Tristan
    Wolff, Michel
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2017, 49 (06) : 782 - 783
  • [4] Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections
    Horcajada, Juan P.
    Montero, Milagro
    Oliver, Antonio
    Sorli, Luisa
    Luque, Sonia
    Gomez-Zorrilla, Silvia
    Benito, Natividad
    Grau, Santiago
    CLINICAL MICROBIOLOGY REVIEWS, 2019, 32 (04)
  • [5] Antimicrobial activity of ceftolozane-tazobactam against multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa clinical isolates from a Spanish hospital
    Isabel Lopez-Calleja, Ana
    Morilla Morales, Elena
    Nunez Medina, Rossi
    Fernandez Esgueva, Marta
    Sahagun Pareja, Juan
    Garcia-Lechuz Moya, Juan Manuel
    Ferrer Ceron, Isabel
    Vinuelas Bayon, Jesus
    Rezusta Lopez, Antonio
    REVISTA ESPANOLA DE QUIMIOTERAPIA, 2019, 32 (01) : 68 - 72
  • [6] Ceftolozane/Tazobactam Treatment of Multidrug-resistant Pseudomonas aeruginosa Infections in Children
    Molloy, Leah
    Abdulhamid, Ibrahim
    Srivastava, Ruma
    Ang, Jocelyn Y.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2020, 39 (05) : 419 - 420
  • [7] A Multicenter Evaluation of Ceftolozane/Tazobactam Treatment Outcomes in Immunocompromised Patients With Multidrug-Resistant Pseudomonas aeruginosa Infections
    Hart, Delaney E.
    Gallagher, Jason C.
    Puzniak, Laura A.
    Hirsch, Elizabeth B.
    OPEN FORUM INFECTIOUS DISEASES, 2021, 8 (03):
  • [8] Ceftolozane-tazobactam vs. colistin for the treatment of infections due to multidrug-resistant Pseudomonas aeruginosa : a multicentre cohort study
    Almangour, Thamer A.
    Aljabri, Ahmad
    Al Musawa, Mohammed
    Almohaizeie, Abdullah
    Almuhisen, Sara
    Damfu, Nader
    Alfozan, Awaly
    Alraddadi, Basem M.
    Alattas, Majda
    Qutub, Mohammed
    Alhameed, Abrar F.
    Khuwaja, Malik
    Alghamdi, Ahlam
    Binkhamis, Khalifa M.
    Alfahad, Wafa
    AIShahrani, Fatimah S.
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2022, 28 : 288 - 294
  • [9] Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: A Multicenter Study
    Gallagher, Jason C.
    Satlin, Michael J.
    Elabor, Abdulrahman
    Saraiya, Nidhi
    McCreary, Erin K.
    Molnar, Esther
    El-Beyrouty, Claudine
    Jones, Bruce M.
    Dixit, Deepali
    Heil, Emily L.
    Claeys, Kimberly C.
    Hiles, Jon
    Vyas, Nikunj M.
    Bland, Christopher M.
    Suh, Jin
    Biason, Kenneth
    McCoy, Dorothy
    King, Madeline A.
    Richards, Lynette
    Harrington, Nicole
    Guo, Yi
    Chaudhry, Saira
    Lu, Xiaoning
    Yu, Daohai
    OPEN FORUM INFECTIOUS DISEASES, 2018, 5 (11):
  • [10] Evaluation of ceftazidime/avibactam for serious infections due to multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa
    Rodriguez-Nunez, Olga
    Ripa, Marco
    Morata, Laura
    de la Calle, Cristina
    Cardozo, Celia
    Feher, Csaba
    Pellice, Martina
    Valcarcel, Andrea
    Puerta-Alcalde, Pedro
    Marco, Francesc
    Garcia-Vidal, Carolina
    del Rio, Ana
    Soriano, Alex
    Antonio Martinez-Martinez, Jose
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2018, 15 : 136 - 139
12345